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Myc is an enigma wrapped in a mystery. Attempts to identify Myc target genes, particularly in
cancer, have been fraught with dead ends and context-specific functions. Lin et al. and Nie et al.
address this conundrumby showing thatMyc acts to amplify the output of existing transcriptionally
active genes.Originally discovered as a stowaway in
some defective avian retroviruses that
acutely elicit myelocytic leukemia, Myc
rose to notoriety both as the prototyp-
ical cooperating oncogene that, together
with Ras, can oncogenically transform
fibroblasts in vitro and as one of the imme-
diate early growth response genes that are
rapidly induced in various cell types upon
mitogenic stimulation. Myc is a member
of a class of dimeric transcription factor—
the basic-helix-loop-helix-leucine zipper
proteins and, as a heterodimer with its
partner protein Max, binds DNA, with
a predilection for a palindromic E-box
element CACGTG. Myc is widely, almost
universally, present in proliferating normal
somatic cells and expression of Myc
protein and mRNA, both of which are
very short-lived, are continuously depen-
dent upon mitogenic signaling. By
contrast, Myc expression in cancer cells
is typically deregulated and elevated.
Finally, ectopic expression of Myc is,
alone, able to induce proliferation of
many adult somatic cell types, whereas
cells denuded of Myc, whether normal or
neoplastic, replicate very slowly, if at all.
Distill this heady brew together, and we
are left with a transcription factor that
exerts its biological activity through themodulation of target genes involved in
cell replication.
Since then, however, our under-
standing of Myc has been painfully slow.
Efforts to identify Myc target genes
suggest that Myc modulates up to a third
of the transcriptome. Whatever the latest
trend in cancer biology—cell cycle, cell
growth, apoptosis, metabolism, cancer
stem cells, micro RNAs, angiogenesis,
inflammation—Myc is in there regulating
most of the key genes. Attempts to iden-
tify a unitary Myc signature have likewise
been frustrated by the cell-type- and
cell-context-dependent nature of Myc
activity. Myc seems to be all things to all
people. Myc is like the Cheshire cat in
Alice: the longer you study its ‘‘function,’’
the more elusive it becomes and, in the
end, all that is left is a derisive smile and
a hint of leucine zipper.
But now, two papers published in this
issue of Cell (Lin et al., 2012 and Nie
et al., 2012) may offer some relief,
although their conclusions may not bring
comfort because they conclude that
Mycdoes not andneverwill haveone tran-
scriptional signature. Rather, they suggest
that the activity of Myc is completely
contextual and depends upon cell type
and status. Both papers address thequestion of what elevated levels of Myc
do (that physiological levels may not).
The stark conclusions from both papers,
which are reached through genome-wide
CHIP-Seq analysis and sophisticated
data extraction, are that, rather than
engaging its dedicated own transcrip-
tional program, Myc serves to amplify the
output of existing transcriptionally active
genes. Put simply, Myc is a general ampli-
fier of any given transcriptional state a cell
finds itself in at the time of Myc activation
(Figure 1). Both groups demonstrate that
as Myc protein levels rise, Myc is loaded
quantitatively onto active promoters (as
demonstrated by co-occupancy of RNA
pol II and the presence of active chromatin
marks), enhancing their transcription. By
contrast, Myc does not localize to the
promoters of silent genes, suggesting
that Myc cannot itself not instruct de
novo gene activation. Hence, Myc is
a contingent transcriptional amplifier.
Interestingly,Mycamplification is logarith-
mic, disproportionally enhancing tran-
scription of highly active genes. Of note,
the loading of Myc on active genes
remains dependent upon specific
CACGTG E-box elements within each
target gene’s promoter and proximity of
such E boxes to the transcriptional starteptember 28, 2012 ª2012 Elsevier Inc. 11
Figure 1. Myc Is an Amplifier, Not a Specifier, of Transcriptional Activation
Image was designed by Rafael Casellas and Ethan Taylor.site (TSS) appears to correlate with highly
expressed genes.
For years, one conundrum in Myc
biology has been the role played by
elevated Myc expression in cancer cells.
Is elevation of Myc merely a spandrel
byproduct of the various oncogenic muta-
tions that deregulate its expression or
does excess Myc do oncogenic things
that less Myc doesn’t do? For example,
by binding lower affinity E-box elements,
preternaturally elevated levels of Myc
might commandeer supernumerary genes
with oncogenic activity into the Myc
pantheon. Both studies indicate that this
is not the case. They show that increasing
Myc levels does indeed result in loading of
Myc onto lower affinity noncanonical
E-boxes, typically in enhancer regions
more distant from the TSS; however, this
occurs only in those genes at which Myc12 Cell 151, September 28, 2012 ª2012 Elseis already bound via canonical CACGTG
E-box elements. Hence, more Myc
increases transcription only from those
genes that are already Myc targets but
not from new genes. Both groups suggest
that increased Myc occupancy promotes
transcriptional elongation and Lin et al.
show increased occupancy of the elonga-
tion factor pTEF-b at Myc bound sites
when Myc level is elevated and increased
phosphorylation at a serine residue in
RNA pol II associated with elongation
rather than transcriptional initiation,
consistent with the appearance of pol II in
gene bodies (Nie et al.). This underpins
previous data in which Myc was found to
be important for transcriptional pause
release of Pol II (Rahl et al., 2010). The
elevated levels of Myc in tumor cells exac-
erbate existing Myc functions—they do
not recruit new ones.vier Inc.So the idea that emerges from these
data is thatMyc acts as a general amplifier
or augmentor of transcription, serving to
lock the transcriptional program in place
andbuffer cells against transientperturba-
tions and exigencies. This satisfyingly
explains the elusiveness of the ‘‘Myc
signature’’—in essence, the Myc signa-
ture is an entirely contextual construct:
a consequence of each cell’s state rather
than a cause. However, this straightfor-
ward and unifying model has some prob-
lems. First, ifMyc serves to reinforce exist-
ing states, one would surely imagine that
it would be induced and engaged by
all types of instructional signals—for
example, factors that induce differentia-
tion and senescence. However, Myc acti-
vation by and large seems to be the exclu-
sive purview of mitogenic signals. Indeed,
persistent Myc expression typically locks
cells in a continually proliferating state
and renders them refractory to signals
that would otherwise promote growth
arrest and terminal differentiation. This
private relationship between Myc and mi-
togenesis argues for a rathermorespecific
role for Myc, as a coordinator of cell prolif-
eration. Furthermore, Myc is not limited
merely to reinforcing an existing cellular
state—it can also instruct them: expres-
sion of Myc alone, even at physiological
levels, is sufficient to drive quiescent
mesenchymal, epithelial and lymphoid
cells to proliferate and, concurrently, to
engage all the diverse biological programs
that proliferating cells need to grow and
expand into the soma—for example, the
switch to biosynthetic ‘‘Warburg’’ metab-
olism and activation of cell growth and
the production of the inflammatory and
angiogenic signals required to remodel
surrounding stroma and blood vessels.
One possible way to accommodate the
apparent contradiction that Myc rein-
forces any pre-existing transcriptional
state with the general observation that
Myc activation selectively drives prolifera-
tion and dedifferentiation is to invoke the
idea that differing levels of Myc are re-
quired to engage different biological
outputs. Only low levels of Myc can en-
gage proliferation, whereas higher levels
are needed to lock in other phenotypes
such as differentiation. However, once
proliferation is engaged, it secondarily
represses differentiation—hence the ob-
served outcome that Myc induces cell
proliferation and dedifferentiation. The
notion that cells respond to different
Myc levels in different ways is in accord
with the observations by Nie et al. (2012)
that increasing levels of Myc load only
onto already active genes, logarithmically
but selectively increasing their output: the
tacit implication of this is that cells have
evolved to sense differential Myc levels.
Indeed, we already know that different
Myc levels do elicit different outputs—
physiological levels of Myc are sufficient
to drive proliferation but aberrantly ele-
vated levels trigger apoptosis (Murphy
et al., 2008). This reflects the general
principle that our evolved tumor suppres-
sion mechanisms seem to discriminate
between normal and oncogenic signals
by sensing the aberrantly elevated flux of
oncogenic signals (Feldser et al., 2010;
Junttila et al., 2010; Murphy et al., 2008).
However, unlike proliferation and differen-
tiation, which are mutually contradictory,
proliferation and apoptosis are not—theearliest studies showed that both prolifer-
ation and apoptosis occur together in
populations of cells harboring high levels
of Myc. If proliferation negates differentia-
tion, and the augmentation of the dif-
ferentiated state only arises at Myc levels
that have already engaged proliferation,
when would this higher threshold ever
be biologically relevant?
Such questions, and countless others,
are sure to keep the upcoming generation
of cancer biologists busy and the current
ones out of retirement. What we do
have, thanks to these two seminal
studies, is the glimpse of a coherent and
holistic view of Myc. We have come
a long way since the 1980s’ view wherein
Myc exerted its pleiotropic biological
effects through just a few, critical target
genes, whose identification would unlock
Myc’s mysteries. Now Myc regulates
a third of everything—and which third
depends on everything else. It’s strange
the way things turn out.Cell 151, SREFERENCES
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